Yesterday, Aug. 12, 2015, 119 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $99.99 to $15,899,263.45.

Highlighted Stocks Traded by Insiders:

Molson Coors Brewing (TAP) - FREE Research Report

Herington Charles M, who is Director at Molson Coors Brewing, sold 13,785 shares at $72.61 on Aug. 12, 2015. Following this transaction, the Director owned 23,470 shares meaning that the stake was reduced by 37% with the 13,785-share transaction.

The shares most recently traded at $71.63, down $0.98, or 1.36% since the insider transaction. Historical insider transactions for Molson Coors Brewing go as follows:

  • 4-Week # shares sold: 404
  • 12-Week # shares sold: 404
  • 24-Week # shares sold: 9,904

The average volume for Molson Coors Brewing has been 1.5 million shares per day over the past 30 days. Molson Coors Brewing has a market cap of $11.8 billion and is part of the consumer goods sector and food & beverage industry. Shares are down 3.07% year-to-date as of the close of trading on Wednesday.

Molson Coors Brewing Company manufactures and sells beer and other beverage products. The stock currently has a dividend yield of 2.26%. The company has a P/E ratio of 37.2. Currently, there are 5 analysts who rate Molson Coors Brewing a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TAP - FREE

TheStreet Quant Ratings rates Molson Coors Brewing as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Molson Coors Brewing Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Keryx Biopharmaceuticals (KERX) - FREE Research Report

Madison Greg, who is President and CEO at Keryx Biopharmaceuticals, sold 1,683 shares at $6.07 on Aug. 12, 2015. Following this transaction, the President and CEO owned 106,735 shares meaning that the stake was reduced by 1.55% with the 1,683-share transaction.

The shares most recently traded at $6.05, down $0.02, or 0.33% since the insider transaction. Historical insider transactions for Keryx Biopharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 2,758
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 5,787
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 13,577

The average volume for Keryx Biopharmaceuticals has been 1.5 million shares per day over the past 30 days. Keryx Biopharmaceuticals has a market cap of $655.2 million and is part of the health care sector and drugs industry. Shares are down 54.35% year-to-date as of the close of trading on Wednesday.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Currently, there are 6 analysts who rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KERX - FREE

TheStreet Quant Ratings rates Keryx Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Keryx Biopharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Huntsman (HUN) - FREE Research Report

Stryker David M, who is Exec VP, GC and Sec at Huntsman, bought 1,000 shares at $17.59 on Aug. 12, 2015. Following this transaction, the Exec VP, GC and Sec owned 51,712 shares meaning that the stake was boosted by 1.97% with the 1,000-share transaction.

The shares most recently traded at $16.68, down $0.91, or 5.46% since the insider transaction. Historical insider transactions for Huntsman go as follows:

  • 4-Week # shares bought: 170
  • 4-Week # shares sold: 26,974
  • 12-Week # shares bought: 170
  • 12-Week # shares sold: 26,974
  • 24-Week # shares bought: 170
  • 24-Week # shares sold: 26,974

The average volume for Huntsman has been 2.8 million shares per day over the past 30 days. Huntsman has a market cap of $4.3 billion and is part of the basic materials sector and chemicals industry. Shares are down 25.5% year-to-date as of the close of trading on Wednesday.

Huntsman Corporation, together with its subsidiaries, manufactures and sells differentiated organic and inorganic chemical products worldwide. The company operates in five segments: Polyurethanes, Performance Products, Advanced Materials, Textile Effects, and Pigments and Additives. The stock currently has a dividend yield of 2.87%. The company has a P/E ratio of 22.9. Currently, there are 5 analysts who rate Huntsman a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HUN - FREE

TheStreet Quant Ratings rates Huntsman as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Huntsman Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.